Publication: Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand
1
Issued Date
1998-08-20
Resource Type
ISSN
02699370
Other identifier(s)
2-s2.0-15644370351
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
AIDS. Vol.12, No.12 (1998), 1521-1527
Suggested Citation
Vina Churdboonchart, Ronald B. Moss, Worachart Sirawaraporn, Buranaj Smutharaks, Reungpung Sutthent, Fred C. Jensen, Prawut Vacharak, Janet Grimes, Georgia Theofan, Dennis J. Carlo Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS. Vol.12, No.12 (1998), 1521-1527. doi:10.1097/00002030-199812000-00015 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18377
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand
Other Contributor(s)
Abstract
Objective: To examine the effect of treatment with an inactivated, gp120-depleted, HIV-1 immunogen (Remune) in 30 Thai subjects infected with HIV-1 subtype E. Design: Sixty-week open-label study. Methods: Thirty HIV-positive volunteers with CD4 cell counts ≤ 300 x 106/l were given intramuscular injections of Remune into the triceps muscle on day 1 and then at weeks 4, 8, 12, 24, 36, 48 and 60. Results: Treatment with Remune was well-tolerated and augmented HIV-l-specific immune responses. Furthermore, subjects had a significant increase in CD4 cell count (P < 0.0001), CD4 cell percentage (P < 0.0001), CD8 cell percentage (P < 0.0001), and body weight (P < 0.0001) compared with pretreatment levels. Fourteen subjects with detectable viral load at day 1 showed a decrease at week 60 (P = 0.04). Retrospective Western blot analysis showed 23 subjects with increased intensity of antibody bands and 15 patients showed development of new reactivities to HIV proteins, especially towards p17 and p15. Conclusion: These results indicate that HIV-specific immune-based therapeutic approaches such as Remune should be further examined in countries with different clades of HIV-1 and where access to antiviral drug therapies is limited.